Paediatric Oncology in India for African Children: Childhood Cancer Treatment Guide 2026
Priya Sharma
Oncology & Cancer Care Writer
Paediatric Oncology in India for African Children: Childhood Cancer Treatment Guide 2026
Every year, approximately 400,000 children worldwide are diagnosed with cancer. Eighty percent of these children live in low- and middle-income countries — predominantly in Africa, South Asia, and Latin America — yet these regions receive only a fraction of global childhood cancer treatment resources. In many African countries, the five-year survival rate for childhood cancer is below 20%. In India's leading paediatric oncology centres, the same diseases are being cured in 60–80% of cases.
This disparity is not about the children. It is about access. India's paediatric oncology infrastructure — built over decades at centres like Tata Memorial Hospital in Mumbai — now offers African families access to world-class childhood cancer treatment at costs that are a fraction of European or North American alternatives.
Key fact: Acute lymphoblastic leukaemia (ALL), the most common childhood cancer, has a cure rate exceeding 80% with BFM-based protocols at India's leading paediatric oncology centres — comparable to outcomes in Europe and the USA.
Africa's Childhood Cancer Burden
Sub-Saharan Africa has the highest under-five mortality from cancer globally. The reasons are multiple:
Late diagnosis: The absence of routine screening and low awareness among parents and primary health workers means many African children with cancer present at advanced stages.
Limited specialist care: Paediatric oncologists are extremely rare in most African countries. The WHO estimates the entire African continent has fewer than 200 trained paediatric oncologists, compared to thousands in North America and Europe.
Treatment abandonment: Even when childhood cancer is diagnosed, families often abandon treatment due to cost, distance from the treating centre, drug supply interruptions, or loss of faith in the process when complications arise.
Burkitt lymphoma: A rapidly growing tumour of B-cell lymphocytes that is dramatically more common in equatorial Africa than elsewhere in the world, driven by the Epstein-Barr virus-malaria co-infection pathway. Burkitt lymphoma is actually highly curable with the right chemotherapy, but requires prompt, protocol-based treatment.
India addresses each of these barriers for African families who can access the India treatment pathway.
Most Common Childhood Cancers Treated in India for African Children
Acute Lymphoblastic Leukaemia (ALL)
ALL is the most common childhood cancer worldwide, accounting for approximately 25–30% of all childhood cancers. It affects the blood and bone marrow, where immature white blood cells (lymphoblasts) proliferate uncontrollably.
Symptoms: Pallor (anaemia), easy bruising and bleeding (thrombocytopenia), bone pain, fever, enlarged lymph nodes and spleen, fatigue.
Treatment: Intensive chemotherapy using the BFM (Berlin-Frankfurt-Münster) or similar protocol over two to three years — induction (one month), consolidation, and maintenance phases. India's leading paediatric oncology centres follow modified BFM protocols.
Outcomes: Overall cure rate 80–85% in standard-risk ALL at India's top centres. High-risk ALL (with certain genetic features or slow initial response) has 60–70% cure rates with intensified protocols and, where needed, bone marrow transplantation.
Cost in India: $8,000–15,000 for the first year (induction through early maintenance). Long-term maintenance can be managed partially in Africa with telemedicine oversight from India.
Burkitt Lymphoma
Burkitt lymphoma (BL) is a rapidly growing B-cell lymphoma that is endemic in equatorial Africa (associated with Epstein-Barr virus and repeated malaria infection). It typically presents as a jaw or facial mass in younger children, or as abdominal swelling in older children.
Despite its aggressive growth, Burkitt lymphoma is highly chemosensitive. Short-course intensive chemotherapy (COPAD, CODOX-M/IVAC, or modified regimens) achieves 70–80% cure rates in limited-stage disease.
Key message: Time is critical for Burkitt lymphoma — the tumour can double in size in 24 hours. Swift diagnosis and treatment initiation is essential.
Cost in India: $7,000–14,000 for a complete treatment course (usually 3–6 months of intensive chemotherapy).
Wilms Tumour (Nephroblastoma)
Wilms tumour is a kidney cancer occurring predominantly in children under five years of age. It presents as an abdominal mass, often discovered by a parent during bathing. It is one of the most curable childhood solid tumours — even metastatic Wilms tumour has a 70–80% cure rate with multimodal treatment.
Treatment: The SIOP (European) approach used in India involves initial chemotherapy to shrink the tumour before surgery (nephrectomy — removal of the affected kidney), followed by further chemotherapy and sometimes radiation. The kidney is removed laparoscopically at many Indian centres.
Cost in India: $10,000–18,000 for surgery plus chemotherapy.
Retinoblastoma
Retinoblastoma is a rare eye tumour arising in the retina of young children, typically diagnosed before age five. The classic presenting sign is a white pupillary reflex (leukocoria) — a white glow in the eye visible in flash photographs. It is the most common intraocular tumour in children.
In most African countries, retinoblastoma is treated by enucleation (removal of the affected eye) because chemotherapy access is limited and the tumour is often advanced at presentation. In India, eye-salvage therapy — using systemic chemotherapy, intra-arterial chemotherapy into the ophthalmic artery, and laser or cryotherapy to destroy residual tumour — can preserve the eye and useful vision in many cases.
Key centres in India: LV Prasad Eye Institute (Hyderabad) and Sankara Nethralaya (Chennai) have India's most experienced retinoblastoma teams, with published outcomes comparable to international benchmarks.
Cost in India: $6,000–12,000 depending on laterality (one or both eyes) and number of treatment cycles required.
Bone Tumours (Osteosarcoma and Ewing Sarcoma)
Bone cancers in children, particularly osteosarcoma (most common in the knee region) and Ewing sarcoma, are challenging conditions requiring chemotherapy, surgery (limb-salvage if possible, amputation if not), and sometimes radiation. India's orthopaedic oncology teams at Tata Memorial and Apollo have significant experience with limb-salvage surgery using custom implants.
Cost in India: $15,000–25,000 depending on whether limb-salvage or amputation surgery is performed.
Top Paediatric Oncology Centres in India
Tata Memorial Hospital, Mumbai: India's national cancer institute and the leading centre for childhood cancer. The paediatric oncology division handles hundreds of new patients per year and has a dedicated Children's Cancer Unit. International patient services are available. As a government hospital, costs are lower than private alternatives.
Rajiv Gandhi Cancer Institute, Delhi: Dedicated cancer hospital with an active paediatric oncology programme. Modern facilities and experienced multidisciplinary team.
Apollo Children's Hospital, Chennai: Private hospital with dedicated paediatric oncology inpatient unit. Strong international patient infrastructure.
AIIMS Delhi (Paediatrics/Oncology): Academic excellence with access to clinical trials. Government pricing makes it among the most affordable options.
Narayana Health, Bangalore: Known for high-quality, value-driven cancer care. Paediatric oncology programme with experienced team.
What to Expect: The Treatment Journey for Paediatric Cancer Patients
Before You Travel
Share all existing diagnostic reports — biopsy results, bone marrow aspirate, imaging — with Arodya for oncologist review. An Indian paediatric oncologist will confirm or modify the diagnosis and outline a treatment plan before you travel. This avoids repeating expensive investigations unnecessarily.
Arrival and Workup
On arrival, the Indian paediatric oncology team will complete any outstanding staging investigations and confirm the treatment protocol. Most children are admitted within one to two days of arrival for treatment initiation — time matters in many childhood cancers.
Inpatient Treatment
The induction phase of chemotherapy for leukaemia involves four weeks of intensive inpatient or day-patient treatment with close monitoring. Children with solid tumours (Wilms, Burkitt) may undergo initial chemotherapy before surgical resection. Parents stay with their child in most Indian paediatric wards — rooms for one accompanying parent are standard.
Return Home and Maintenance
After completing induction and consolidation treatment in India, families can often return home for the maintenance phase of treatment — provided a local paediatrician or oncologist can administer medications and monitor blood counts under the Indian team's supervision. Arodya facilitates telemedicine follow-up to bridge the Indian specialist and the local doctor.
To discuss your child's situation and understand what India's paediatric oncology centres can offer, start your enquiry with Arodya. Every day matters in childhood cancer — and we will move quickly to get you answers.
For information on supporting a child's treatment journey, see our first-time travel guide for India.
Bone Marrow Transplantation for Childhood Cancer in India
For children with high-risk ALL, relapsed ALL, or aplastic anaemia, bone marrow transplantation (haematopoietic stem cell transplantation, HSCT) may be the recommended treatment. India has dedicated bone marrow transplant units at several paediatric centres:
Tata Memorial Hospital, Mumbai: Paediatric BMT unit with experience in matched sibling donor, matched unrelated donor, and haploidentical (half-matched parent donor) transplantation.
Apollo Children's Hospital, Chennai: BMT programme with paediatric-specific protocols.
CMC Vellore: Christian Medical College has one of India's longest-standing and most respected BMT programmes.
Cost: Bone marrow transplantation for paediatric ALL in India costs $25,000–45,000 depending on donor type and complications — approximately 75–80% less than European or North American pricing ($120,000–200,000). The HLA typing and donor search process, conditioning chemotherapy and radiation, transplant admission (typically four to six weeks), and initial follow-up are included.
Haploidentical transplantation: For children without a matched sibling donor, haploidentical transplantation using a parent as donor has become a viable option at experienced Indian BMT centres, driven by improved graft-versus-host disease prevention protocols. This means virtually every child who needs BMT has a potential donor — a parent is always half-matched.
Immunotherapy and Targeted Therapy for Paediatric Cancer in India
Modern childhood cancer treatment increasingly incorporates targeted therapies and immunotherapy:
Blinatumomab (Blincyto): A bispecific T-cell engager antibody for relapsed/refractory B-cell ALL. Available at Indian oncology centres, including through compassionate access programmes that reduce cost.
Inotuzumab ozogamicin: For relapsed B-cell ALL, this antibody-drug conjugate achieves high remission rates.
CAR-T cell therapy: India is at the early stages of offering chimeric antigen receptor T-cell therapy (CAR-T), which has transformed outcomes in relapsed/refractory ALL in high-income countries. Tata Memorial Hospital is part of ongoing CAR-T trials and compassionate access programmes. This is the frontier of paediatric oncology in India.
For children with solid tumours, targeted therapy based on molecular profiling (next-generation sequencing of the tumour) is available at major Indian centres, identifying druggable mutations that may guide treatment in relapsed or refractory cases.
A Word to Families
Parents of children with cancer carry an almost unbearable weight. The diagnosis, the uncertainty, the fear — these are universal. What makes the Africa-India pathway different from simply hoping for the best at a local hospital is the combination of genuine clinical excellence, humane care, and accessible cost.
Tata Memorial Hospital has treated thousands of children from across South Asia and Africa. Their paediatric oncologists have seen nearly every presentation of childhood cancer and have protocols for all of them. They are not learning on your child — they are applying decades of accumulated expertise.
Your child's chance at a cure is real. India can make it reachable.
